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This issue of Current Oncology, the fifth of six is-
sues scheduled for 2007, reflects the increased and
continuing interest in and support for the journal. The
seven original manuscripts included in the issue—
reflecting a wide range of interests within the oncol-
ogy community—make it one of the largest to date.
The Practice Guidelines section includes four
articles: optimal chemotherapy treatment for recur-
rent ovarian cancer, highlighting the search for alter-
native agents following failure of platinum therapy;
the use of Gliadel wafers in the management of ma-
lignant glioma; the treatment of depression in cancer
patients, with its unique problems; and the Canadian
Supportive Care Group’s consensus on the manage-
ment of anemia in cancer patients. I am also delighted
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An incorrect table was submitted earlier this year as
part of the article “Canadian recommendations for
the treatment of glioblastoma multiforme” (Mason
WP, Del Maestro R, Eisenstat D, et al. Curr Oncol
2007;14(3):110–17). The corrected version follows:
at the inclusion of a guest editorial, “Updates and
developments in radiation oncology: times of prac-
tice change,” by Drs. Carolyn Freeman and Ervin
Podgorsak. Two additional articles address the role
of cancer antigen 125 in ovarian cancer surveillance
and how symptom clustering is being studied in can-
cer patients and what the implications may be.
As announced on the journal’s Web site,
www.current-oncology.com, Current Oncology has
now been added to the list of publications accepted
for Journal Selector, a database of detailed profiles
of leading biomedical journals produced by PeerView
Inc. that acts as a resource for authors who are decid-
ing which journal is most appropriate for publication
of their work.
ERRATUM
TABLE  I Effect of methylation status of methylguanine DNA
methyltransferase (MGMT) promoter on progression-free survival
(PFS) and overall survival (OS) in patients receiving radiotherapy
plus temozolomide (TMZ) versus radiotherapy (RT) alone a
Clinical endpoint TMZ + RT RT
(n=106) (n=100)
Methylated MGMT (n)4 6 4 6
6-Month PFS 68.9 47.8
2-Year OS 46.0 22.7
Unmethylated MGMT (n)6 0 5 4
6-Month PFS 40.0 35.2
2-Year OS 13.8 <2
a Adapted from Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene
silencing and benefit from temozolomide in glioblastoma. N Engl
J Med 2005;352:997–1003.
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